Literature DB >> 2625681

Seropositive rheumatoid arthritis in monozygotic twin sisters carrying HLA-DR4 or DR4 associated with B27.

U Tarp1, H K Graudal.   

Abstract

We have followed 3 pairs of monozygotic twin sisters with seropositive rheumatoid arthritis (RA) since 1966, 1971 and 1975. RA developed in the probands at the age of 25, 39 and 21 years and in the cotwins 37, 8 and 19 years later, respectively. Two pairs, Nos 1 and 3, were discordant when first seen. Only Pair 1 had a family history of RA. Onset of RA was not related to marital status or pregnancy. It was improbable that contagious infections of childhood or seasonal infections could be important triggers of RA. Since the concordance rate for RA in monozygotic twins depends on the duration of the observation period, the previously stated concordance rate of 30% may be questioned.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2625681

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Polygenic susceptibility in rheumatoid arthritis.

Authors:  P Wordsworth; J Bell
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

2.  Rheumatoid arthritis in twins: a study of aetiopathogenesis based on the Australian Twin Registry.

Authors:  N Bellamy; D Duffy; N Martin; J Mathews
Journal:  Ann Rheum Dis       Date:  1992-05       Impact factor: 19.103

3.  The radiographic features of rheumatoid arthritis in HLA-B27-positive patients.

Authors:  J H Rundback; Z S Rosenberg; G Solomon
Journal:  Skeletal Radiol       Date:  1993       Impact factor: 2.199

4.  A methodological appraisal of the impact of different classification procedures used in three different phases of the australian rheumatoid arthritis twin survey.

Authors:  N Bellamy; D L Duffy; P Sambrook; R R Buchanan; P M Brooks; H Dunckley; S C Healey; S Mason; N G Martin
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 5.093

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.